Marc Rubin
CIK 1412377 · Executive Chairman · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$52.8K
Companies
6
Total Filings
68
Lifetime Open-Market Net
-$476.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRIS | Director | 1,405 | $4.83 | $6.8K | $55.3K | 23 | 2026-07-09 |
| GALT | Director | 13,581 | $3.39 | $46.0K | -$713.8K | 13 | 2025-01-27 |
| TITAN PHARMACEUTICALS INC (TTNP) Delisted | Executive Chairman | 155 | $4.61 | $715 | $116.2K | 10 | 2022-01-05 |
| GALECTIN THERAPEUTICS INC (GALTW) Delisted | Director | 17,446 | — | — | $26.1K | 4 | 2016-12-19 |
| MEDX | Director | — | $36.03 | — | $0 | 3 | 2009-03-09 |
| TITAN PHARMACEUTICALS INC (TTP) Delisted | President & Chief Ex Officer | 132,500 | $47.61 | $6.31M | $40.0K | 4 | 2008-10-22 |
Recent Filings · Page 2 of 7
68 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-31 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2022-01-25 | GALT | Grant (A) | — | $0 | EDGAR |
| 2022-01-05 | TITAN PHARMACEUTICALS INC (TTNP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-29 | GALT | Grant (A) | — | $0 | EDGAR |
| 2021-02-11 | TITAN PHARMACEUTICALS INC (TTNP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-29 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2020-03-04 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2020-01-13 | GALT | Grant (A) | — | $0 | EDGAR |
| 2019-04-03 | TITAN PHARMACEUTICALS INC (TTNP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-25 | GALT | Mixed | −7,000 | -$202.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.